Antidiabetic medications and weight gain: implications for the practicing physician
- PMID: 19490828
- DOI: 10.1007/s11892-009-0040-7
Antidiabetic medications and weight gain: implications for the practicing physician
Abstract
Obesity is a major risk factor for diabetes and cardiovascular disease, and most people with diabetes are overweight or obese. Weight reduction has been shown to improve glycemic control and reduce cardiovascular risk in the diabetic population. While physicians strive to achieve better glycemic control for their patients with diabetes, they are faced with the problem of weight gain that is commonly encountered with the use of antidiabetic agents, particularly insulin, insulin secretagogues, and thiazolidinediones. Weight gain in this population could offset the beneficial effects of good glycemic control and discourage patients from adhering to treatment. In this review, we discuss the effects of the various antidiabetic agents on body weight, highlighting the potential mechanisms and the implications of weight gain in this population. We also present the available therapeutic modalities that have the potential of achieving better glycemic control without adverse effects on body weight.
Similar articles
-
Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.Treat Endocrinol. 2003;2(1):33-47. doi: 10.2165/00024677-200302010-00004. Treat Endocrinol. 2003. PMID: 15871553 Review.
-
Oral antidiabetic agents: current role in type 2 diabetes mellitus.Drugs. 2005;65(3):385-411. doi: 10.2165/00003495-200565030-00005. Drugs. 2005. PMID: 15669880 Review.
-
Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.Can J Diabetes. 2015 Dec;39 Suppl 5:S148-54. doi: 10.1016/j.jcjd.2015.09.090. Can J Diabetes. 2015. PMID: 26654858 Review.
-
Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.Int J Clin Pract Suppl. 2007 Aug;(154):19-28. doi: 10.1111/j.1742-1241.2007.01441.x. Int J Clin Pract Suppl. 2007. PMID: 17593274 Review.
-
Effect of thiazolidinediones on body weight in patients with diabetes mellitus.Am J Med. 2003 Dec 8;115 Suppl 8A:42S-48S. doi: 10.1016/j.amjmed.2003.09.005. Am J Med. 2003. PMID: 14678865 Review.
Cited by
-
Hydrogel-based Drug Delivery System in Diabetes Management.Pharm Nanotechnol. 2024;12(4):289-299. doi: 10.2174/0122117385266276230928064235. Pharm Nanotechnol. 2024. PMID: 37818559 Review.
-
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes.Curr Atheroscler Rep. 2024 Jan;26(1):1-10. doi: 10.1007/s11883-023-01181-4. Epub 2023 Dec 27. Curr Atheroscler Rep. 2024. PMID: 38148417 Free PMC article. Review.
-
Prevalence and factors associated with overweight and obesity among patients with type 2 diabetes mellitus in Uganda-a descriptive retrospective study.BMJ Open. 2020 Nov 4;10(11):e039258. doi: 10.1136/bmjopen-2020-039258. BMJ Open. 2020. PMID: 33148749 Free PMC article.
-
Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study.Indian J Endocrinol Metab. 2017 Mar-Apr;21(2):286-292. doi: 10.4103/ijem.IJEM_517_16. Indian J Endocrinol Metab. 2017. PMID: 28459027 Free PMC article.
-
Association between hedonic hunger and glycemic control in non-obese and obese patients with type 2 diabetes.J Diabetes Investig. 2018 Sep;9(5):1135-1143. doi: 10.1111/jdi.12800. Epub 2018 Feb 7. J Diabetes Investig. 2018. PMID: 29328544 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical